Hoth Therapeutics Inc (HOTH)
$0.75
+0.01
(+1.17%)▲
Performance
- $0.74$0.76$0.75
1.73%
Downside
Day's Volatility :3.03%
Upside
1.32%
- $0.58$1.73$0.75
22.67%
Downside
52 Weeks Volatility :66.47%
Upside
56.65%
Returns
| Period | Hoth Therapeutics Inc | Index (Russel 2000) |
|---|---|---|
3 Months | -14.66% | 0.0% |
6 Months | -37.42% | 0.0% |
1 Year | -45.58% | 0.0% |
3 Years | -97.43% | -21.1% |
Highlights
Market Capitalization | 5.2M |
Book Value | $1.74 |
Earnings Per Share (EPS) | -1.57 |
Wall Street Target Price | 4.5 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -42.66% |
Return On Equity TTM | -77.36% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -14.1M |
Diluted Eps TTM | -1.57 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.28 |
EPS Estimate Next Year | -0.72 |
EPS Estimate Current Quarter | -0.43 |
EPS Estimate Next Quarter | -0.43 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 500.0%
Technicals Summary
Sell
Neutral
Buy
Hoth Therapeutics Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Hoth Therapeutics Inc | -31.73% | -37.42% | -45.58% | -97.43% | -99.29% |
 Regeneron Pharmaceuticals, Inc. | -11.94% | 13.03% | 20.97% | 85.64% | 232.53% |
 Novo Nordisk A/s | -12.38% | -3.12% | 17.52% | 138.65% | 361.43% |
 Alnylam Pharmaceuticals, Inc. | 7.18% | 92.5% | 69.12% | 39.45% | 259.26% |
 Vertex Pharmaceuticals Incorporated | -0.75% | 21.23% | 29.84% | 165.64% | 177.5% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Hoth Therapeutics Inc | NA | NA | NA | -1.28 | -0.77 | -0.43 | NA | 1.74 |
Regeneron Pharmaceuticals, Inc. | 26.88 | 26.88 | 1.38 | 45.01 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 40.83 | 40.83 | 1.8 | 3.37 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.38 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.58 | 0.33 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Hoth Therapeutics Inc | Buy | $5.2M | -99.29% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $110.1B | 232.53% | 26.88 | 32.04% |
Novo Nordisk A/s | Buy | $523.9B | 361.43% | 40.83 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $36.5B | 259.26% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $124.3B | 177.5% | 32.84 | -4.74% |
Insights on Hoth Therapeutics Inc
Vs ALNY
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 69.1% return, outperforming this stock by 114.7%
Vs VRTX
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 39.4% return, outperforming this stock by 136.8%
Institutional Holdings
Armistice Capital, LLC
3.09%UBS Group AG
0.63%Vanguard Group Inc
0.56%Geode Capital Management, LLC
0.52%Morgan Stanley - Brokerage Accounts
0.14%Tower Research Capital LLC
0.11%
Company Information
hoth therapeutics, inc., a biopharmaceutical company, focuses on developing therapies for dermatological disorders. the company focuses on therapies for patients suffering from indications, including eczema, chronic wounds, psoriasis, asthma, and acne. it intends to use the biolexa platform to develop two topical cream products that treat eczema and reduces post-procedure infections for patients undergoing aesthetic dermatology procedures. the company has license agreements with the george washington university; the university of maryland baltimore; isoprene pharmaceuticals, inc.; the north carolina state university; chelexa biosciences, inc.; and the university of cincinnati. it also has a partnership agreement with zyl㶠therapeutics inc. co-develop a new topical treatment for patients with cutaneous lupus erythematosu, a chronic autoimmune disease that affects the skin and is associated with a significant burden on patient quality of life. hoth therapeutics has research collaboratio
Organization | Hoth Therapeutics Inc |
Employees | 2 |
CEO | Mr. Robb Knie |
Industry | Pharmaceuticals: Major |
Discover More
Orion Energy Systems Inc
$0.75
+1.17%
Nano Labs Ltd.
$0.75
+1.17%
Innovator Intl Developed Power Buffer Etf - June
$0.75
+1.17%
Bny Mellon Concentrated Intl
$0.75
+1.17%
Fidelity International Multifactor Etf
$0.75
+1.17%
Innovator Us Equity Accelerated Plus Etf - April
$0.75
+1.17%
Amplify Seymour Cannabis Etf
$0.75
+1.17%
Saratoga Investment Corp
$0.75
+1.17%
Ebang International Holdings Inc
$0.75
+1.17%